{"entity":{"id":"paper-radiant-3-everolimus-pnet-yao-nejm-2011","kind":"paper","name":"RADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours","aka":[],"tldr":"The mTOR inhibitor everolimus more than doubled the time to progression in advanced pancreatic neuroendocrine tumours, becoming one of the first two targeted drugs approved for the disease in 2011.","summary":"Phase 3 placebo-controlled trial of 410 patients with advanced, low- or intermediate-grade, progressive pancreatic neuroendocrine tumours randomised to everolimus 10 mg daily or placebo.\n\nMedian progression-free survival was 11.0 versus 4.6 months (hazard ratio 0.35), with stomatitis, rash, diarrhoea and hyperglycaemia as the characteristic toxicities; overall survival was similar because of crossover.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2011","url":"https://doi.org/10.1056/NEJMoa1009290"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/21306238/"}],"tags":[],"related":[],"cancers":["pancreatic-net"],"sections":[],"technologies":[],"targets":[],"drugs":["everolimus"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2011,"doi":"10.1056/NEJMoa1009290","pmid":"21306238","authors":"Yao JC, Shah MH, Ito T, et al.","paperType":"rct","findings":["Median progression-free survival 11.0 vs 4.6 months; hazard ratio 0.35.","Objective response 5 percent; benefit was disease stabilisation."],"whatItMeans":"Everolimus is a standard option for progressive pancreatic neuroendocrine tumours, alongside sunitinib, chemotherapy and radioligand therapy.","caveats":["Crossover obscured any survival benefit.","Hyperglycaemia is a particular concern in this population."],"changedPractice":true,"participants":410},"route":"/key-papers/paper-radiant-3-everolimus-pnet-yao-nejm-2011/","neighbours":{"cancer":[{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/"}],"drug":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}